Protalex Announces Presentation Highlighting PRTX-100 Phase 1b Clinical Data in Patients with Immune Thrombocytopenia at the European Hematology Association 23rd Annual Meeting | Business Wire

Protalex Announces Presentation Highlighting PRTX-100 Phase 1b Clinical Data in Patients with Immune Thrombocytopenia at the European Hematology Association 23rd Annual Meeting | Business Wire: Protalex, Inc. (OTCQB: PRTX), a clinical-stage biopharmaceutical company, today announced that preliminary results from its European Phase 1b open-lab